Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Breast Cancer
Published in: Breast Cancer 1/2003

01-01-2003 | Original Article

Transforming growth factor B1 T29C polymorphism and breast cancer risk in Japanese women

Authors: Asahi Hishida, Hiroji Iwata, Nobuyuki Hamajima, Keitaro Matsuo, Mitsuhiro Mizutani, Takuji Iwase, Shigeto Miura, Nobuhiko Emi, Kaoru Hirose, Kazuo Tajima

Published in: Breast Cancer | Issue 1/2003

Login to get access
Metadata
Title
Transforming growth factor B1 T29C polymorphism and breast cancer risk in Japanese women
Authors
Asahi Hishida
Hiroji Iwata
Nobuyuki Hamajima
Keitaro Matsuo
Mitsuhiro Mizutani
Takuji Iwase
Shigeto Miura
Nobuhiko Emi
Kaoru Hirose
Kazuo Tajima
Publication date
01-01-2003
Publisher
Springer-Verlag
Published in
Breast Cancer / Issue 1/2003
Print ISSN: 1340-6868
Electronic ISSN: 1880-4233
DOI
https://doi.org/10.1007/BF02967627

Other articles of this Issue 1/2003

Breast Cancer 1/2003 Go to the issue

Original Article

Estimation of individualized probabilities of developing breast cancer for Japanese women

Original Article

Estrogen receptor α mutation (A-to-G transition at nucleotide 908) is not found in different types of breast lesions from japanese women

Editorial

Radiofreauency ablation treatment for breast cancer to meet the next challenge: How to treat primary breast tumor without surgery

Original Article

Detection of MUC1 and keratin 19 mRNAs in the bone marrow by quantitative RT-PCR predicts the risk of distant metastasis in breast cancer patients

Review Article

Clinical efficacy of bisphosphonate therapy for bone metastasis from breast cancer

Review Article

What is the Japanese consensus on adjuvant chemotherapy in breast cancer?
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits